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2

FETAL DAMAGE DUHING ANTICOAGULANT THEHAPY
FOR ANTEPARTUM THROMBOElfffiOLIC DISEASE
Introduction
Although thromboembolic phenomenon occurs
relatively rarely in pregnancy, possible adverse effect
on the fetus during therapy makes it a subject of significant concern in antenatal care.

In this paper the

recent literature is reviewed for the prevalence of the
disease, its pathophysiology, therapy, and the risk to
the fetus.

Four new cases are presented, and the dangers

of anticoagulant therapy are discussed.

Extent and Incidence
Thromboembolic disease may manifest as phlebothrombosis without primary associated inflammation of
the vessel wall.

More commonly there is mural pathology

associated with the attached thrombus wherefore the term
thrombophlebitis is appropriately descriptive.

The in-

volvement of a more vital organ, the lungs, when a dislodged thrombus is carried away by the blood stream causes
a high incidence of sudden deaths and makes pulmonary embolism a dreaded third member of the triad in thromboembolic disease.
Aaro, Johnson, and Juergens l found the most
common type of venous thrombosis associated with pregnancy to be thrombophlebitis of superficial, usually varicose,
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veins of the lower extremity.

Deep venous thromboses

were found in the veins of the lower extremity as well
as in the pelvis.

However, pelvic thrombophlebitis is

stated to be seen most frequently with postpartum infection and sepsis.

The authors found pulmonary em-

bolism in two out of nine cases of antepartum deep
thrombophlebitis.

Husni, Pena, and Lenhart 5 reported

four cases of pulmonary embolism among 20 cases of
superficial and deep thrombophlebitis during pregnancy.
They found that phlebitis occurred predominantly in the
last trimester, and very rarely during the first trimester of pregnancy.

For some unexplained reason Aaro

et all found antepartum thrombophlebitis to have a marked
predilection for the left lower extremity as compared
to an even distribution between the left and the right
legs after pregnancy is terminated.
Ullery6 reported an incidence of antepartum
thrombophlebitis to be 0.018 percent in his series in
1954.

Aaro et all found 87 cases of thrombophlebitis

during 25,082 pregnancies, an incidence of 0.15 percent.
Villasanta 8 reported an incidence of 0.027 percent in
43,790 pregnant women.

Husni et a1 5 reported an inci-

dence of 0.085 percent in 23,485 pregnancies.

Pathophysiology
Since Virchow's triad of conditions predisposing
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to thrombosis were proposed over a century ago, viz.
(1) blood stasis, (2) vessel injury, and (3) hypercoagulability of the blood, very little has been added
to further illuminate the mechanism and biochemistry
of thrombus formation. 7

The precise interrelation of

the various factors involved in the in vivo clotting
Villasanta 8

of blood have not been fully worked up.

states that the proposed theories fail to explain the
relatively low overall incidence of thromboembolic
disease in pregnancy in spite of the conditions in
gestation that enhance intravascular clotting of the
blood:

varicose veins, increased intra-abdominal

pressure on the iliac veins with resultant venous
stasis in the lower extremities; arteriovenous shunt
in the placenta with consequent increased venous incompetency in the lower extremities; anemia; obesity;
and increased blood fibrinogen level.

Furthermore,

Beller 2 observes that in the postpartum period the
concentration of blood coagulation factors declines
from the markedly high levels during pregnancy to
almost normal values by the third postpartum day in
most instances, yet statistically the incidence of pulmonary embolism is highest at this time.

In spite of

our lack of thorough knowledge in this field, significant progress has been made in therapy and prophylaxis
during the past few decades.
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Therapy and Risks
Avoidance of prolonged bed rest, elevation of
the lower extremities, proper hydration, and use of elastic
stockings or elastic wraps on the legs promote good venous
return and comprise accepted practice in prophylaxis for
thrombophlebitis during pregnancy in the more susceptible
patient.

Surgical therapy, exemplified by venous ligation,

vein stripping, and embolectomy is uncommon during pregnancy.

Anticoagulant treatment is today the mainstay in

thromboembolic disease during gestation.
Before anticoagulants came into use, the disease
often progressed to pulmonary embolism and death.

Villa-

santa's9 review of the literature up till 1964 revealed a
mortality of 12.8 percent among 163 pregnant females with
thrombophlebitis who received no anticoagulants.

Among

134 antepartum patients treated with anticoagulants, the
mortality was 0.7 percent.

Heparin, bishydroxycoumarin

(Dicumarol), or a combination of the two were used.
recently dextran has been found promising. 3 ,5,8

More

Heparin

prolongs the clotting time by acting as an antithrombin
and antithromboplastin.

The coumarin derivatives, known

also as the oral anticoagulants, act indirectly by depressing formation of blood clotting factors II, VII, IX,
and X.

Dextran prevents the agglutination of red cells,

decreases the whole blood viscosity, and produces a molecular coating over the intima of the blood vessel.
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Anticoagulant therapy entails definite risks
both to the mother as well as the fetus.

Among contra-

indications to anticoagulant use are thrombocytopenic
purpura, open wounds or ulcerations, impaired hepatic or
renal function, hypertension, subacute bacterial endocarditis, peptic ulcers, colitis, and esophageal varices.
Hemorrhage is the major complication of anticoagulant
therapy.

Vi11asanta 9 nevertheless found in the literature

very few cases of complications to the mother following
anticoagulant treatment.
Possible danger to the human fetus during antepartum anticoagulant therapy could have been predicted
even before the coumarin derivatives were isolated.

It

was after the incrimination of sweet clover eaten by the
pregnant cow as the cause of hemorrhagic disease in newborn calves that investigations by Link and his associates (as narrated by Vigran 7 ) led to the discovery of the
coumarin compounds.

Indeed nature had provided the first

animal experiment for safety of the oral anticoagulants
in pregnancy.

Reports of successful use of coumarin drugs

as well as adverse effects to the fetus without harm to
the mother began to appear after the first use of the
coumarin drugs in antepartum thrombophlebitis in 1945.
Cases of fetal death with maceration of the fetus 4 were
described in association with anticoagulant treatment.
Nevertheless, Ullery6, in 1954, concluded that the risk
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to the mother as well as the fetus was minimal when prothrombin time was maintained between 18 and 23 seconds
(20 to 30 percent of normal).

Villasanta 8 found 17

reported cases of thrombophlebitis treated with heparin
as the sole anticoagulant with no ill effect on the fetus.
In contrast, in 89 published cases treated with coumarin
derivatives, he found 14 cases of fetal death in utero
and four additional cases of fatal hemorrhagic lesions
in the newborn, giving a mortality of 20 percent.

In

another report Villasanta 9 found in the literature two
cases of surviving children with congenital anomalies
related to coagulation defect.

The fatal cases included

a stillborn infant with hemorrhage of the thymus as well
as other organs; a neonatal death with tentorial tears;
another stillborn with multiple hemorrhages; a few cases
of intrauterine death with severe maceration masking possible evidence of hemorrhage; and a case of abortion.
Villasanta found no particular coumarin derivative to be incriminated more than any other.

Similarly.,

the total doses given, as well as the duration of treatment were found to be insignificant.

Extreme prolongation

of the prothrombin time is thought not to be responsible
for the fetal hemorrhages since one mother with prolongation of the prothrombin time to 97 seconds delivered a
normal baby whereas death from hemorrhages were reported
in cases with maintenance of prothrombin time at recommended
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values.
Four cases of adverse effect to the fetus during
anticoagulant therapy, including two from the University
of Nebraska Hospital, are now presented.

Case Reports
Case No.1
The patient was a 35 year old para 3-0-1-3 whose
last menstrual period was on December 15, 1956, and whose
expected date of confinement was September 22, 1957.

This

patient had severe rheumatic heart disease and had been on
anticoagulants for some years, primarily on bishydroxycoumarin (Dicumarol).
on digitalis.

Because of fibrillation, she was also

The general trend had been to maintain a

prothrombin time around 30 to 40 percent of normal, seldom
ranging below 25 percent.

The obstetrician's office

records contain the following laboratory values:
Date

Prothrombin time

March 11, 1967

37 percent

March 26, 1967

40 percent

April 23, 1967

21 percent

June 25, 1967

15 percent

Between the office visit on June 25 and the next
one a week later, fetal heart tones and fetal movements
had disappeared.

The patient delivered spontaneously by

breech presentation five weeks prematurely.

The fetus was
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estimated to have been dead in utero for three weeks.

Un-

fortunately, a postmortem examination was not performed.
Records do not show evidence of gross hemorrhagic lesions.

Case No.2
This 21 year old Negro female para 2-1-0-2 with
a history of the last menstrual period on September 8,
1963, and an expected term date of June 15, 1964 was admitted to the hospital on October 14, 1963, for thrombophlebitis of the right lower extremity.

She had a past

history of recurrent thromboplhebitis and grand mal epilepsy.

She was said to have had either plication or

ligation of the inferior vena cava early in 1963.

Records

show the following drug doses and laboratory values:

Date

Sodium Warfarin
(Coumadin) Dose

Prothrombin
Time

Control

October 15

40 mgm

18 sec

13 sec

October 16

20 mgm

22 sec

12 sec

October 17

10 mgm

29 sec

12 sec

October 19

5 mgm

October 20

5 mgm

38 sec

12 sec

October 21

5 mgm

October 22

5 mgm

35 sec

14 sec

10

Additionally, 100 mgm of heparin TID was given
on October 15, 16, and 17.
during hospitalization.

She also received phenylbutazone

Diphenylhydantoin (Dilantin) and

primidone (Mysoline) prescribed during her hospital stay
were continued upon discharge in October following satisfactory recovery.

Anticoagulants were discontinued after

October 22.
The patient was readmitted on November 24 with
recurrence of the thrombophlebitis in the right lower extremity.

She was given phenylbutazone, and anticoagulants

were given according to the following schedule with the
laboratory values as shown:

Date

Sodium Warfarin
(Coumadin) Dose

Prothrombin
Time

Control

November

4

40 mgm

November

5

10 mgm

14 sec

12 sec

November

6

5 mgm

22 sec

12 sec

November

7

5 mgm

27 sec

12 sec

November

8

5 mgm

28 sec

13 sec

November

9

26 sec

12 sec

22 sec

12 sec

November 10

7.5 mgm

November 11

7.5 mgm

November 12

10 mgm

22 sec

12 sec

November 13

15 mgm

15 sec

13 sec

14 sec

12 sec

November 14
November 15

30 mgm
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Date

Sodium Warfarin
(Coumadin) Dose

Prothrombin
Time

Control

November 16

5 mgm

30 sec

13 sec

November 17

5 mgm

30 sec

13 sec

November 18

5 mgm

29 sec

14

November 19

17.5 mgm

25 sec

13 sec

24 sec

13 sec

31 sec

13 sec

November 22

34 sec

13 sec

November 23

22 sec

13 seC

18 sec

13 sec

November 20
November 21

November 24

5 mgm

7.5 mgm

November 25
November 26

15 mgm

November 27

15 mgm

17 sec

13 sec

November 28

15 mgm

21 sec

12 sec

November 29

10 mgm

31 sec

14 sec

November 30

7.5 mgm

44 sec

14 sec

December

1

7.5 mgm

33 sec

13 sec

December

2

7.5 mgm

37 sec

13 sec

December

3

10 mgm

The patient was dismissed from the hospital on
December 3 and arrangements were made for a visiting nurse
to supervise an alternating warfarin dose of 7.5 mgm and
10 mgm per day_

Blood was obtained on an outpatient basis

for the following prothrombin time values:
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Date

Prothrombin Time

Control

December

3

29 sec

13 sec

December

9

35 sec

14 sec

December 16

19 sec

13 sec

December 23

46 sec

14 sec

December 30

53 sec

14 sec

On December 23 the drug dose was increased to
10 mgm daily following the preceding week's low prothrombin time.

On December 30 warfarin was stopped when the

prothrombin time for the previous week was seen to be 46
seconds.

She received 5 mgm of the drug on January 1,

and 7.5 mgm on January 2.
On the morning of January 3 she was admitted
in active labor with vaginal bleeding.

Fifteen mgm of

phytonadione (Aquamephyton) was administered after the
prothrombin time was found to be 24 seconds.
stillborn female was delivered.

A 5 lb. 1 oz.

No record of an autopsy

or description of any obvious hemorrhage are found.

Case No.3
This 38 year old white female para 3-0-1-3 with
a history of the last menstrual period on June 20, 1965,
and estimated date of term of March 27, 1966 was hospitalized
at another hospital from October 13 until October 19 for
right axillary vein thrombophlebitis.

She had a long term
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history of bleeding tendencies.

Sodium Warfarin
(Coumadin) Dose

Date
October 13
October 14

50 mgm

October 15

15 mgm

October 16

7.5 mgm

October 17

10 mgm

October 18

10 mgm

October 19

Records show the following:

Prothrombin
Time

Control

12.5 sec

12 sec

22 sec

11 sec

25 sec

12 sec

30 sec

12 sec

7.5 mgm

A total of 350 mgm of heparin was given on the
13th and a clotting time of 40 minutes is recorded.

From

the 14th until the 17th of October, she received 200 mgm
of heparin daily.
14.

Clotting time was 27 minutes on October

She also received phenylbutazone (Butazolidin) while in

the hospital.

She was dismissed on October 19 on 7.5 mgm

of warfarin daily.

During an office visit on October 25

her prothrombin time was 31 seconds with a control of 14
seconds.
On November 10 the patient was admitted again,
for acute and chronic abdominal pain.

Prothrombin time was

found to be 18 seconds with a control of 11 seconds.

Micro-

hematuria was seen, and a possibility of internal hemorrhage
prompted cessation of anticoagulant administration at this
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time.

She was dismissed after a few days with no further

anticoagulant therapy.
The patient was seen for the first time at the
University Hospital for a prenatal checkup on December 10.
During subsequent visits she gave a history of spotting on
December 14, and bleeding hemorrhoids on December 20.
She was admitted to the University Hospital on
March 14, 1966, for chronic back pain, obesity, mild hypertension, fatigue from overwork, and for observation for
possible future recurrence of axillary vein thrombosis
during the remainder of her pregnancy.

Following a rela-

tively uneventful course she delivered an 8 lb. 14 oz.
female infant with hydrocephalus after oxytocin induction.
At approximately one month of age, the child underwent a
craniotomy at which time an old hematoma, estimated to be
formed prenatally, was found.

The child is institution-

alized at the present time.

Case No.4
This 22 year old white female nullipara was admitted to the hospital on February 20, 1967, with a diagnosis
of a missed abortion.
July 1, 1967.

Her estimated date of confinement was

She had a past history of pulmonary embolism

treated with vena cava plication and ligation of the ovarian
veins.

On a previous admission, she was started on sodium

warfarin (Coumadin) prophylaxis when it was learned that

15

she was pregnant.

The following drug doses and laboratory

values are available:

Sodium Warfarin
(Coumadin) Dose

Date
December

8

December

9

December 10

Prothrombin
Time

Control

13 sec

13 sec

16 sec

14 sec

40 mgm
7.5 mgm

December 11

10 mgm

14 sec

13 sec

December 13

10 mgm

32 sec

13 sec

December 14

10 mgm

December 15

15 mgm

18 sec

13 sec

December 16

10 mgm

18 sec

13 sec

From December 16 until December 21 the patient
received 10 mgm of the drug daily.

From December 22 until

January 25 she took 7.5 mgm daily.

From January 26 until

delivery after hospitalization on February 20, 5 mgm
and 7.5 mgm were prescribed on alternate days.

Prothrombin

time after December 16 are shown below:

Date

Prothrombin Time

Control

December 22

37 sec

13 sec

December 29

32 sec

13 sec

January 5

24 sec

13 sec

January 26

32 sec

13 sec

February 9

22 sec

13 sec

February 23

19 sec

13 sec
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A few days after admission she went spontaneously
into labor and delivered a dead male fetus.

Other data

are not available on the fetus.

Comments
The four cases presented add to the mounting
evidence against the use of the coumarin drugs during pregnancy.

However, controlled studies are lacking on the

subject apparently due to the relative rarity of the
disease during pregnancy.

In the cases found in the li-

terature as well as those presented here, unequivocal
evidence of hemorrhage is lacking in a large percentage
of the fetuses lost.

It is therefore not surprising that

proponents of continued utilization of oral anticoagulants
in pregnancy as well as those convinced otherwise are both
found at present.
There is little doubt that heparin is safe for
the fetus when given to the mother with careful maintenance
of clotting time within a recommended range.

Its safety

lies in its high molecular weight of around 20,000 that
probably prohibits passage through the placenta.

On the

other hand a molecular weight of approximately 1,000 apparently allows the coumarin drugs to pass through the placental barrier and into the fetus.

The fortuitous phe-

nomenon that results are not disastrous to a larger percentage of fetuses is explained by Be11er 2 to be due to a
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compensation mechanism for the inadequate production of
coagulation factors in the fetal liver.

Despite the

deficiency of blood coagulation factors, the bleeding
and clotting time in the newborn as well as the fetus are
found to be shorter than in the adult.

Hemorrhagic

complications in the fetus are thought to arise when
these unknown compensatory mechanisms are functioning
improperly.
Studies on the treatment of acute thrombophlebitis with dextran have aroused enthusiasm among
investigators.

Cox, Flotte, and Buxton 3 reported in 1965

on the treatment of thrombophlebitis with dextran of
average molecular weight of 75,000 as well as with dextran 40,000.

They found that as the time interval be-

tween onset of symptoms and the initiation of therapy
passes 48 hours the chances of objective improvement are
much reduced.

When used within 48 hours of onset of symp-

toms it was found to be an effective treatment.

Husni

et a1 5 reported in 1967 on 20 cases of antepartum deep
thrombophlebitis treated either conservatively, with
anticoagulants, or with dextran.

They found a remarkably

good response to dextran with no untoward results to the
fetus.
Unfortunately, dextran cannot completely replace
the coumarin drugs in pregnancy in spite of its apparent
advantages of relative ease of administration and the lack
of a need for specific laboratory control.

Nevertheless, an
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attempt to use dextran instead of the coumarin compounds
in acute antepartum thrombophlebitis merits serious consideration.
The low cost of the oral anticoagulants plus
the ease of administration which make them suitable for
outpatient therapy undoubtedly are the major factors that
account for their popularity both in antepartum and in
general use.

Clearly, research is indicated to discover

new anticoagulants which would combine the above advantages with characteristics that guarantee safety to the
fetus.

In the meantime perhaps an extra effort should be

made by the clinician to replace the coumarins with the
other available therapeutic agents, heparin and dextran,
where feasible.

Summary
Thromboembolic phenomenon characterized by thrombophlebitis, phlebothrombosis, and pulmonary embolism is
rare during pregnancy.

Pathophysiology of the disease is

poorly understood.
Anticoagulant therapy markedly reduces the associated high mortality.

The coumarin drugs are incriminated

in adverse effect on the fetus during antepartum thrombophlebitis in the four cases presented, adding mounting
evidence against their use in pregnancy.

Until new and

safer drugs are available, heparin and dextran should be
utilized where possible.
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